[425] Sonnet BioTherapeutics Holdings, Inc. Business Combination Communication
Filing Impact
Filing Sentiment
Form Type
425
Filed by Hyperliquid Strategies Inc
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Sonnet BioTherapeutics Holdings, Inc.
Commission File No. 001-35570
Date: November 18, 2025
Sonnet Biotherapeutc Hldng Inc
NASDAQ:SONN
SONN Rankings
SONN Latest News
SONN Latest SEC Filings
SONN Stock Data
33.39M
6.80M
4.4%
5.56%
27.33%
Biotechnology
Pharmaceutical Preparations
United States
PRINCETON